Positronen-Emissions-Tomographie bei Karzinomen des oberen Gastrointestinaltrakts

Zusammenfassung

Die Behandlungsmöglichkeiten bei gastro-ösophagealen Karzinomen reichen von der limitierten Resektion bis hin zu multimodaler Therapie in den lokalisierten Stadien und enden bei Chemotherapie und Symptom-orientierter Behandlung im Falle fortgeschrittener Erkrankung. Eine akkurate klinische Festlegung des Tumorstadiums sowie darüber hinausgehende prognostische und prädiktive Informationen bilden idealerweise die Grundlage für die Wahl des geeigneten Therapieverfahrens. Die Positronen-Emissions-Tomographie in Kombination mit der Computertomographie, heutzutage vorzugsweise in Form des Hybridbildgebungsverfahrens PET/CT, kann die Genauigkeit des klinischen Stagings verbessern und zusätzliche prognostische Informationen liefern. Darüber hinaus weisen die Erfahrungen spezialisierter Zentren darauf hin, dass PET auch die Responseevaluation im Rahmen präoperativer Chemotherapie oder Radiochemotherapie signifikant verbessern könnte. Dieser Artikel stellt den aktuellen Stellenwert der PET für das Staging und die multimodale Therapie gastro-ösophagealer Karzinome dar. Zum jetzigen Zeitpunkt bleibt allerdings unklar, ob die Prognose von Patienten tatsächlich verbessert werden kann, wenn man die PET in die Diagnostik und Behandlung gastro-ösophagealer Karzinome integriert. Prospektive Multicenterstudien werden benötigt, um die Genauigkeit metabolischer Schwellenwerte zu bestätigen und den Stellenwert PET-gesteuerter Behandlungsalgorithmen zu erhärten.

Abstract

Treatment options for gastro-esophageal cancers reach from limited resection to multimodality treatment in localized stages and end with chemotherapy and symptom-oriented care in advanced disease. Accurate clinical assessment as well as prognostic and predictive information is needed for selecting the appropriate treatment approach. Positron emission tomography (PET) in combination with computed tomography (CT) in a hybrid imaging modality PET/CT may refine the staging accuracy and add prognostic information. Moreover, experiences from diverse centers indicate that PET also might improve significantly the assessment of response to preoperative chemotherapy and chemoradiotherapy. This article outlines the current value of PET in the staging and multidisciplinary care of gastro-esophageal cancer. However, at this stage it remains unclear if the prognosis of patients can be improved by implementing PET in the management of these tumors. Prospective multicenter studies have to be performed to validate metabolic cut-off values and to proof the benefit of PET-guided treatment decisions.

Positronen-Emissions-Tomographie - Staging - Therapieansprechen - Ösophaguskarzinom - Magenkarzinom

positron emission tomography - staging - treatment response - esophageal cancer - gastric cancer

Literatur

• 1 Beyer T, Townsend D W, Brun T. et al . A combined PET/CT scanner for clinical oncology.  J Nucl Med. 2000;  41 1369-1379
• 2 Boellaard R, Krak N C, Hoekstra O S. et al . Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study.  J Nucl Med. 2004;  45 1519-1527
• 3 Boellaard R, O’Doherty M J, Weber W A. et al . FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0.  Eur J Nucl Med Mol Imaging. 2010;  37 181-200
• 4 Boellaard R, Oyen W J, Hoekstra C J. et al . The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials.  Eur J Nucl Med Mol Imaging. 2008;  35 2320-2333
• 5 Brücher B L, Weber W, Bauer M. et al . Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography.  Ann Surg. 2001;  233 300-309
• 6 Downey R J, Akhurst T, Ilson D. et al . Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial.  J Clin Oncol. 2003;  21 428-432
• 7 Flamen P, Lerut A, Van Cutsem E. et al . Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma.  J Clin Oncol. 2000;  18 3202
• 8 Flamen P, Van Cutsem E, Lerut A. et al . Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer.  Ann Oncol. 2002;  13 361-368
• 9 Gillham C M, Lucey J A, Keogan M. et al . (18)FDG uptake during induction chemoradiation for oesophageal cancer fails to predict histomorphological tumour response.  Br J Cancer. 2006;  95 1174-1179
• 10 Herrmann K, Ott K, Buck A K. et al . Imaging gastric cancer with PET and the radiotracers 18F-FLT and 18F-FDG: a comparative analysis.  J Nucl Med. 2007;  48 1945-1950
• 11 Javeri H, Xiao L, Rohren E. et al . Influence of the baseline 18F-fluoro-2-deoxy-D-glucose positron emission tomography results on survival and pathologic response in patients with gastroesophageal cancer undergoing chemoradiation.  Cancer. 2009;  115 624-630
• 12 Javeri H, Xiao L, Rohren E. et al . The higher the decrease in the standardized uptake value of positron emission tomography after chemoradiation, the better the survival of patients with gastroesophageal adenocarcinoma.  Cancer. 2009;  115 5184-5192
• 13 Kamangar F, Dores G M, Anderson W F. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world.  J Clin Oncol. 2006;  24 2137-2150
• 14 Kim M K, Ryu J S, Kim S B. et al . Value of complete metabolic response by (18)F-fluorodeoxyglucose-positron emission tomography in oesophageal cancer for prediction of pathologic response and survival after preoperative chemoradiotherapy.  Eur J Cancer. 2007;  43 1385-1391
• 15 Klaeser B, Nitzsche E, Schuller J C. et al . Limited predictive value of FDG-PET for response assessment in the preoperative treatment of esophageal cancer: results of a prospective multi-center trial (SAKK 75/02).  Onkologie. 2009;  32 724-730
• 16 Levine E A, Farmer M R, Clark P. et al . Predictive value of 18-fluoro-deoxy-glucose-positron emission tomography (18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer.  Ann Surg. 2006;  243 472-478
• 17 Lordick F, Ott K, Krause B J. et al . PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial.  Lancet Oncol. 2007;  8 797-805
• 18 Lordick F, Ruers T, Aust D E, et E uropean Organisation of Research and Treatment of Cancer(EORTC) Gastrointestinal Group. Workshop on the role of metabolic imaging in the neoadjuvant treatment of gastrointestinal cancer.  Eur J Cancer. 2008;  44 1807-1819
• 19 Ott K, Weber W A, Lordick F. et al . Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction.  J Clin Oncol. 2006;  24 4692-4698
• 20 Peng H Q, Halsey K, Sun C C. et al . Clinical utility of postchemoradiation endoscopic brush cytology and biopsy in predicting residual esophageal adenocarcinoma.  Cancer Cytopathol. 2009;  117 463-472
• 21 Räsänen J V, Sihvo E I, Knuuti M J. et al . Prospective analysis of accuracy of positron emission tomography, computed tomography, and endoscopic ultrasonography in staging of adenocarcinoma of the esophagus and the esophagogastric junction.  Ann Surg Oncol. 2003;  10 954-960
• 22 Ribi K, Koeberle D, Schuller J C. et al . Is a change in patient-reported dysphagia after induction chemotherapy in locally advanced esophageal cancer a predictive factor for pathological response to neoadjuvant chemoradiation?.  Support Care Cancer. 2009 Feb 7. [Epub ahead of print]; 
• 23 Rizk N, Downey R J, Akhurst T. et al . Preoperative 18[F]-fluorodeoxyglucose positron emission tomography standardized uptake values predict survival after esophageal adenocarcinoma resection.  Ann Thorac Surg. 2006;  81 1076-1081
• 24 Robert-Koch-Institut (Hrsg.) und Gesellschaft der Epidemiologischen Krebsregister in Deutschland e. V. (Hrsg.) .Krebs in Deutschland – Häufigkeiten und Trends. 7. Auflage. Berlin; 2010
• 25 Sarkaria I S, Rizk N P, Bains M S. et al . Post-treatment endoscopic biopsy is a poor-predictor of pathologic response in patients undergoing chemoradiation therapy for esophageal cancer.  Ann Surg. 2009;  249 764-767
• 26 Schomburg A, Bender H, Reichel C. et al . Standardized uptake values of fluorine-18 fluorodeoxyglucose: the value of different normalization procedures.  Eur J Nucl Med. 1996;  23 571-574
• 27 Shields A F, Grierson J R, Dohmen B M. et al . Imaging proliferation in vivo with [F-18]FLT and positron emission tomography.  Nat Med. 1998;  4 1334-1336
• 28 Sobin L H, Gospodarowicz M K, Wittekind C. UICC: TNM classification of malignant tumors. 7th edition. Oxford: Wiley-Blackwell; 2009
• 29 Stahl A, Ott K, Weber W A. et al . FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings.  Eur J Nucl Med Mol Imaging. 2003;  30 288-295
• 30 Swisher S G, Erasmus J, Maish M. et al . 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma.  Cancer. 2004;  101 1776-1785
• 31 Vallböhmer D, Hölscher A H, Dietlein M. et al . [18F]-Fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemoradiation in esophageal cancer.  Ann Surg. 2009;  250 888-894
• 32 van Vliet E P, Heijenbrok-Kal M H, Hunink M G. et al . Staging investigations for oesophageal cancer: a meta-analysis.  Br J Cancer. 2008;  98 547-557
• 33 van Westreenen H L, Cobben D C, Jager P L. et al . Comparison of 18F-FLT PET and 18F-FDG PET in esophageal cancer.  J Nucl Med. 2005;  46 400-404
• 34 van Westreenen H L, Westerterp M, Bossuyt P M. et al . Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer.  J Clin Oncol. 2004;  22 3805-3812
• 35 Vrieze O, Haustermans K, De Wever W. et al . Is there a role for FGD-PET in radiotherapy planning in esophageal carcinoma?.  Radiother Oncol. 2004;  73 269-275
• 36 Wahl R L, Jacene H, Kasamon Y, Lodge M A. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors.  J Nucl Med. 2009;  50 Suppl 1 122S-150S
• 37 Warburg O H, Posener K, Negelein E. Stoffwechsel der Carcinomzelle.  Biochemische Zeitschrift. 1924;  152 319-344
• 38 Weber W A, Ott K, Becker K. et al . Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging.  J Clin Oncol. 2001;  19 3058-3065
• 39 Wieder H A, Beer A J, Lordick F. et al . Comparison of changes in tumor metabolic activity and tumor size during chemotherapy of adenocarcinomas of the esophagogastric junction.  J Nucl Med. 2005;  46 2029-2034